CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 15 enrolled
Drug / intervention
Rifabutin +1 moredrug
Likely dose
Rifabutin 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01894776
NCT01894776Phase 1Completed
CompareCT.gov

A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc

Ottawa Hospital Research Institute·interventional·Posted Jul 10, 2013·Updated Mar 10, 2020

In Brief

A Phase 1 clinical trial evaluating Rifabutin and Maraviroc for HIV Infection and 2 related conditions. Completed, enrolled 15 participants across 1 site.

Detailed Summary

Healthy volunteers are being recruited for this pharmacokinetics study. The objective is to characterize the pharmacokinetic properties of maraviroc alone and when administered with rifabutin and to assess rifabutin and 25-O-desacetyl-rifabutin pharmacokinetics compared to the literature.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infection, HIV-1 Infection, Mycobacterium Avium Complex (MAC)
CountriesCanada
CollaboratorsPfizer

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 10, 2013
Enrollment StartJun 1, 2013
Primary CompletionDec 1, 2013
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 13.0 years ago

Interventions

Rifabutindrug

Substance: Rifabutin Daily dose: oral, 300 mg once daily (8:00 am) for 10 days

Maravirocdrug

Substance maraviroc daily dose 300 mg twice daily (8:00 am and 8:00 pm) for 15 days